tiprankstipranks
Advertisement
Advertisement

AQST Stock Latest News

Aquestive Therapeutics files to sell 230,271 shares of common stock for holders
The FlyAquestive Therapeutics files to sell 230,271 shares of common stock for holders
15d ago
AQST
BTIG’s Brisebois Reiterates Buy on Aquestive Therapeutics, Calling Sell-Off Overdone After SPRY Payer Update and Highlighting Limited Scope of FDA CRL for Anaphylm
PremiumRatings
BTIG’s Brisebois Reiterates Buy on Aquestive Therapeutics, Calling Sell-Off Overdone After SPRY Payer Update and Highlighting Limited Scope of FDA CRL for Anaphylm
16d ago
AQST
Aquestive Shareholders Back Directors, Pay Plan, Auditor
PremiumCompany Announcements
Aquestive Shareholders Back Directors, Pay Plan, Auditor
1M ago
8K
AQST
Aquestive Therapeutics Charts Cautious, Liquid Path Forward
PremiumCompany Announcements
Aquestive Therapeutics Charts Cautious, Liquid Path Forward
2M ago
AQST
Aquestive Therapeutics Signals Momentum In Earnings Call
PremiumCompany Announcements
Aquestive Therapeutics Signals Momentum In Earnings Call
2M ago
AQST
Midday Fly By: Cisco reports Q3 beat, Chinese firms cleared to buy Nvidia chips
PremiumThe FlyMidday Fly By: Cisco reports Q3 beat, Chinese firms cleared to buy Nvidia chips
2M ago
AEM
FNV
Aquestive Secures New Oaktree Term Loan to Fund Anaphylm
Premium
Company Announcements
Aquestive Secures New Oaktree Term Loan to Fund Anaphylm
2M ago
8K
AQST
Aquestive Therapeutics reports Q1 EPS (7c), consensus (13c)
Premium
The Fly
Aquestive Therapeutics reports Q1 EPS (7c), consensus (13c)
2M ago
AQST
Aquestive Therapeutics options imply 7.1% move in share price post-earnings
PremiumThe Fly
Aquestive Therapeutics options imply 7.1% move in share price post-earnings
2M ago
AQST
AQST Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
AQST Upcoming Earnings Report: What to Expect?
2M ago
AQST
Aquestive Therapeutics assumed with an Outperform at Oppenheimer
PremiumThe Fly
Aquestive Therapeutics assumed with an Outperform at Oppenheimer
3M ago
AQST
Investor Sue Aquestive Therapeutics Over ‘Postage Stamp’ Anaphylaxis Treatment Claims
PremiumMarket News
Investor Sue Aquestive Therapeutics Over ‘Postage Stamp’ Anaphylaxis Treatment Claims
3M ago
AQST
Aquestive Therapeutics Faces Investor Lawsuit Over Alleged Misleading Statements About Anaphylm FDA Approval Timeline 
PremiumClass ActionAquestive Therapeutics Faces Investor Lawsuit Over Alleged Misleading Statements About Anaphylm FDA Approval Timeline 
3M ago
AQST
Aquestive Advances Anaphylm NDA Resubmission After FDA Meeting
Premium
Company Announcements
Aquestive Advances Anaphylm NDA Resubmission After FDA Meeting
3M ago
8K
AQST
Aquestive Therapeutics completes Type A meeting with FDA for Anaphylm NDA
Premium
The Fly
Aquestive Therapeutics completes Type A meeting with FDA for Anaphylm NDA
3M ago
AQST
Aquestive Therapeutics Announces Key Legal Leadership Transition
PremiumCompany Announcements
Aquestive Therapeutics Announces Key Legal Leadership Transition
4M ago
8K
AQST
Aquestive chief legal officer, chief compliance officer Lori Braender steps down
PremiumThe Fly
Aquestive chief legal officer, chief compliance officer Lori Braender steps down
4M ago
AQST
Aquestive Therapeutics Faces Investor Lawsuit Over Alleged FDA Approval Misrepresentations for Anaphylm
PremiumClass Action
Aquestive Therapeutics Faces Investor Lawsuit Over Alleged FDA Approval Misrepresentations for Anaphylm
4M ago
AQST
Reiterating Buy on Aquestive: Near-Term Cost Pressures Offset by Anaphylm-Driven 2027 Growth Potential and $10 Target
PremiumRatings
Reiterating Buy on Aquestive: Near-Term Cost Pressures Offset by Anaphylm-Driven 2027 Growth Potential and $10 Target
4M ago
AQST
Aquestive Therapeutics Maps Risky Path to ANNAFILM Launch
PremiumCompany AnnouncementsAquestive Therapeutics Maps Risky Path to ANNAFILM Launch
4M ago
AQST
AI Execution Risks Threaten Aquestive Therapeutics’ Competitiveness and Profitability
Premium
Company Announcements
AI Execution Risks Threaten Aquestive Therapeutics’ Competitiveness and Profitability
4M ago
AQST
Aquestive Therapeutics price target lowered to $9 from $12 at Alliance Global
Premium
The Fly
Aquestive Therapeutics price target lowered to $9 from $12 at Alliance Global
4M ago
AQST

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >